Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
CROI 2012: Conference Overview Highlights Biomedical HIV Prevention
- Details
- Category: HIV Prevention
- Published on Tuesday, 06 March 2012 00:00
- Written by Liz Highleyman
HIV prevention was the key theme at Monday's opening press overview of the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), taking place this week in Seattle.
Gilead Requests FDA Approval of Truvada for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 16 December 2011 00:00
- Written by Liz Highleyman
Gilead Sciences announced this week that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) requesting approval of a new indication for Truvada, its tenofovir/emtricitabine combination pill, for HIV pre-exposure prophylaxis (PrEP). If granted, it would be the first antiretroviral to be approved for HIV prevention.
Truvada Drug Levels in Vaginal and Rectal Tissue Offer Clues to HIV PrEP Puzzle
- Details
- Category: HIV Prevention
- Published on Friday, 09 December 2011 00:00
- Written by Liz Highleyman
The 2 drugs in the Truvada pill -- tenofovir and emtricitabine -- reach different concentrations in human cervical, vaginal, and rectal mucosa tissues and fluids, according to new research published in the December 7, 2011, issue of Science Translational Medicine. Lower drug levels in the female genital tract suggest that women may need higher doses to achieve a prophylactic effect, which may help explain conflicting results from some recent biomedical HIV prevention trials. 
Math Model Suggests PrEP plus ART Would Lower HIV Drug Resistance
- Details
- Category: HIV Prevention
- Published on Tuesday, 13 December 2011 00:00
- Written by Liz Highleyman
An appropriate combination of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) could potentially reduce the prevalence of drug-resistant HIV in resource-limited countries, but the wrong balance could increase resistance and the need for second-line therapy, according to a mathematical model described in the December 7, 2011, Nature Scientific Reports.
VOICE HIV Prevention Trial Halts Tenofovir Gel Arm
- Details
- Category: HIV Prevention
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
On November 25 the National Institutes of Health (NIH) and the Microbicide Trials Network (MTN) announced the discontinuation of an arm of the VOICE study that was evaluating a tenofovir vaginal microbicide, due to lack of effectiveness in an interim analysis.
Web Design and Development by